1. Home
  2. SSII vs CTMX Comparison

SSII vs CTMX Comparison

Compare SSII & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SSII

SS Innovations International Inc.

HOLD

Current Price

$3.97

Market Cap

774.5M

Sector

N/A

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$3.76

Market Cap

977.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSII
CTMX
Founded
N/A
2008
Country
India
United States
Employees
483
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
774.5M
977.1M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
SSII
CTMX
Price
$3.97
$3.76
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$12.10
AVG Volume (30 Days)
35.5K
2.8M
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.61
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$3.02
$1.72
52 Week High
$11.87
$8.21

Technical Indicators

Market Signals
Indicator
SSII
CTMX
Relative Strength Index (RSI) 41.76 39.49
Support Level $3.75 $3.39
Resistance Level $5.14 $3.91
Average True Range (ATR) 0.23 0.20
MACD 0.02 0.00
Stochastic Oscillator 34.37 39.76

Price Performance

Historical Comparison
SSII
CTMX

About SSII SS Innovations International Inc.

SS Innovations International Inc is a commercial-stage surgical robotics company. It designs, manufactures, and markets a surgical robotic system called the SSi Mantra Surgical Robotic System (the SSi Mantra) intended for use in urology, general, gynecology, colorectal, gastroenterology, head and neck, thoracic, and cardiac surgeries. Additionally, the company offers a suite of stapling, energy, and core instrumentation for its surgical systems, under the brand name of SSi Mudra.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: